Edgewise (EWTX) insider reports RSU vesting, sell-to-cover and $13.39 option grant
Rhea-AI Filing Summary
Edgewise Therapeutics insider Russell Alan J reported multiple equity transactions on 08/12/2025. He acquired 5,781 shares via vesting of RSUs and sold 1,907 shares in a sell-to-cover to satisfy tax withholding at an average sale price of $13.3924 per share (individual sale prices ranged $13.36–$13.49). After these transactions he beneficially owns 23,400 shares.
The filing also shows newly granted compensation awards: 5,781 RSUs vesting in four equal annual installments beginning 08/12/2025, 28,125 RSUs vesting in four equal annual installments beginning 08/12/2026, and a stock option to purchase 168,750 shares at an exercise price of $13.39 per share exercisable beginning 09/12/2025 with a 08/12/2035 expiration. The report identifies Russell as Chief Scientific Officer and a director.
Positive
- Comprehensive disclosure of RSU grants, option awards, and sell-to-cover transactions provides transparency.
- Long-term incentives granted (RSUs and 10-year option) align executive compensation with shareholder interests.
- Sell-to-cover was limited to tax withholding and not a discretionary large sale.
Negative
- Potential dilution from sizable option (168,750 shares) and RSU pools if fully vested/exercised.
- Material share creation could increase share count over multiple years, impacting per-share metrics if exercised/issued.
Insights
TL;DR: Executive received standard equity compensation and completed a routine sell-to-cover; this is typical for management equity programs.
The report documents non-discretionary and discretionary equity awards consistent with executive compensation: two RSU grant tranches (5,781 and 28,125 RSUs) with multi-year vesting schedules and a sizable stock option (168,750 shares) with a $13.39 exercise price and a ten-year term. The sell-to-cover of 1,907 shares relates solely to tax withholding on RSU vesting and was executed at an average of $13.3924 per share. These items are material to insider dilution and potential future share supply if options are exercised, but they are recorded as routine compensation rather than transactional dispositions for liquidity.
TL;DR: Filing accurately discloses vesting/option mechanics and a tax-related share sale; no unusual trading or large dispositions reported.
The Form 4 shows the reporting person acquired 5,781 shares via RSU vesting and sold 1,907 shares in a sell-to-cover. The option grant vests monthly after a one-month cliff and expires in 2035, which is standard for long-term incentive design. The filing includes an earlier 1,005-share ESPP purchase. All positions are reported as direct ownership. From a compliance perspective, the disclosure is complete and consistent with Section 16 reporting norms.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 5,781 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 28,125 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 168,750 | $0.00 | -- |
| Exercise | Common Stock | 5,781 | $0.00 | -- |
| Sale | Common Stock | 1,907 | $13.3924 | $26K |
Footnotes (1)
- Includes 1,005 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
